|
Basic Characteristics of Mutations
|
|
Mutation Site
|
D614G |
|
Mutation Site Sentence
|
The impairment of viral entry was not affected by virus variants,since efficient inhibition was also observed in six SARS-CoV-2 clinical strains,including the D614G variants which have been shown to exhibit increased infectivity. |
|
Mutation Level
|
Amino acid level |
|
Mutation Type
|
Nonsynonymous substitution |
|
Gene/Protein/Region
|
|
|
Standardized Encoding Gene
|
|
|
Genotype/Subtype
|
- |
|
Viral Reference
|
-
|
|
Functional Impact and Mechanisms
|
|
Disease
|
Cell line
|
|
Immune
|
- |
|
Target Gene
|
-
|
|
Clinical and Epidemiological Correlations
|
|
Clinical Information
|
- |
|
Treatment
|
- |
|
Location
|
- |
|
Literature Information
|
|
PMID
|
33159417
|
|
Title
|
Humanized COVID-19 decoy antibody effectively blocks viral entry and prevents SARS-CoV-2 infection
|
|
Author
|
Huang KY,Lin MS,Kuo TC,Chen CL,Lin CC,Chou YC,Chao TL,Pang YH,Kao HC,Huang RS,Lin S,Chang SY,Yang PC
|
|
Journal
|
EMBO molecular medicine
|
|
Journal Info
|
2021 Jan 11;13(1):e12828
|
|
Abstract
|
To circumvent the devastating pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, a humanized decoy antibody (ACE2-Fc fusion protein) was designed to target the interaction between viral spike protein and its cellular receptor, angiotensin-converting enzyme 2 (ACE2). First, we demonstrated that ACE2-Fc could specifically abrogate virus replication by blocking the entry of SARS-CoV-2 spike-expressing pseudotyped virus into both ACE2-expressing lung cells and lung organoids. The impairment of viral entry was not affected by virus variants, since efficient inhibition was also observed in six SARS-CoV-2 clinical strains, including the D614G variants which have been shown to exhibit increased infectivity. The preservation of peptidase activity also enables ACE2-Fc to reduce the angiotensin II-mediated cytokine cascade. Furthermore, this Fc domain of ACE2-Fc was shown to activate NK cell degranulation after co-incubation with Spike-expressing H1975 cells. These promising characteristics potentiate the therapeutic prospects of ACE2-Fc as an effective treatment for COVID-19.
|
|
Sequence Data
|
EPI_ISL_413592;EPI_ISL_422416;EPI_ISL_447619
|
|
|